The Manufacturers Life Insurance Company Takes Position in DENTSPLY SIRONA Inc. $XRAY

The Manufacturers Life Insurance Company bought a new position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 184,321 shares of the medical instruments supplier's stock, valued at approximately $1,956,000. The Manufacturers Life Insurance Company owned 0.09% of DENTSPLY SIRONA at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Eurizon Capital SGR S.p.A. bought a new stake in DENTSPLY SIRONA during the fourth quarter worth about $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of DENTSPLY SIRONA during the first quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier's stock valued at $35,000 after purchasing an additional 2,122 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of DENTSPLY SIRONA by 119.1% during the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier's stock valued at $43,000 after purchasing an additional 2,051 shares during the last quarter. Finally, Performa Ltd US LLC boosted its position in shares of DENTSPLY SIRONA by 116.1% in the 4th quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 2,283 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Brian T. Gladden acquired 9,985 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, June 15th. The stock was bought at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the acquisition, the director owned 61,849 shares of the company's stock, valued at $619,726.98. This represents a 19.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michael J. Barber bought 15,175 shares of the firm's stock in a transaction on Thursday, June 11th. The stock was acquired at an average cost of $9.88 per share, with a total value of $149,929.00. Following the transaction, the director owned 55,943 shares in the company, valued at $552,716.84. The trade was a 37.22% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 35,160 shares of company stock worth $351,179 over the last quarter. 0.46% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on XRAY. UBS Group reduced their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Thursday, May 7th. BMO Capital Markets reissued a "market perform" rating and issued a $13.00 target price on shares of DENTSPLY SIRONA in a report on Friday, August 7th. Weiss Ratings reissued a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research note on Monday, August 3rd. Barclays raised their price target on DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an "underweight" rating in a report on Monday, August 24th. Finally, Piper Sandler lifted their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 29th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $13.54.

DENTSPLY SIRONA Price Performance

Shares of XRAY opened at $11.43 on Friday. DENTSPLY SIRONA Inc. has a twelve month low of $9.40 and a twelve month high of $14.86. The company has a market capitalization of $2.28 billion, a P/E ratio of -4.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.84. The firm has a 50 day moving average of $12.16 and a 200 day moving average of $11.67. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The business had revenue of $898.00 million for the quarter, compared to analysts' expectations of $889.93 million. During the same period in the prior year, the firm posted $0.52 EPS. The firm's quarterly revenue was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts anticipate that DENTSPLY SIRONA Inc. will post 1.4 earnings per share for the current fiscal year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source